LENZ Therapeutics
LENZ Therapeutics is a late-stage clinical company developing innovative ophthalmic pharmaceutical products that improve vision. Our lead program is an aceclidine based eye drop designed to restore the loss of near vision associated with presbyopia.
Presbyopia
Presbyopia is the gradual and inevitable loss of near vision
Research shows adults over 45 lose on average 1.5 lines of near vision every 6 years1
Most of us first start to notice this as…
- We hold our phones farther from our eyes
- Have difficulty reading a menu in a dimly lit restaurant
Aceclidine
The first and only aceclidine-based eye drop with potential of providing all day seamless vision for the vast majority of presbyopes
- Made possible by aceclidine, our novel active ingredient
- Quickly achieved near vision for on demand needs with a long duration*
- No impact on distance vision in standard and night conditions*
- Potential for broadest target patient population
*Based on Phase 2 study
The Only Pupil Selective Miotic
Aceclidine is the active and new chemical entity in our lead drug
- Unique mode of action
- Targets iris sphincter for pinhole effect
- Predominantly avoids ciliary stimulation preventing unwanted refractive errors
RECENT NEWS
LENZ Therapeutics
LENZ Chief Medical Officer, Marc Odrich, MD will be presenting at [email protected] on Wednesday, 3/1 at the Omni Atlanta Hotel CNN Center. Join the presentation, or connect with us during SECO.
Visit our tabletop booth during the Opening Exhibit Reception on Sunday, February 26th from 6-8pm.
Connect with the LENZ Team at the Telling it Like it is Conference, February 15 – 19, 2023 in Tampa, Florida. This annual, comprehensive Ophthalmology CME Program is lead by LENZ Therapeutics’ Medical Advisory Board member, Dr. Robert Osher.